Navigation Links
Daniel J. Nevrivy, Ph.D., Biotech and Pharmaceutical Patent Attorney, Launches New Law Firm Aimed at Helping Clients Preserve Their Capital

Daniel J. Nevrivy, Ph.D., a Washington, D.C. patent attorney, today announces the formation of Nevrivy Patent Law Group P.L.L.C., a law firm focused on biotechnology and pharmaceutical patent law that aims to help businesses, universities and inventors protect their intellectual property (IP) and preserve their capital.

WASHINGTON (Business Wire EON) December 16, 2008 -- The credit crisis and economic downturn pose extraordinary challenges for many of the nation's leading innovative companies who now find themselves with limited access to dwindling pools of capital to fund their innovation and development needs. "These organizations are finding themselves in a difficult situation, because while they recognize that investments in IP can generate a lot of long term value down the road, they must preserve their capital today to stay in business long enough to reap those rewards. The limited access to capital is forcing companies to make difficult choices about what projects to develop and what to put on hold or abandon," according to Dr. Nevrivy. Research universities are also feeling the pinch, hampered by anticipated budget shortfalls and endowments that have been hard hit by the fall in the stock market.

The fees required to obtain patents and build a valuable portfolio, or identify and analyze competitor patents, can be a very costly and significant expense for many organizations. In addition, billing rates for patent attorneys have soared in recent years, due in large part to increases in salaries and other overhead costs that firms have tried to pass along to clients. "Many law firm cost structures which have been built up over the last several years are not really in sync in today's market with businesses' needs. Businesses are trying to get a better handle on managing their costs because they want to preserve their capital to further their innovation and development goals. It is not clear that they will be able to raise additional capital in the near future," according to Dr. Nevrivy.

With this in mind, Dr. Nevrivy founded the new firm, located in the Georgetown area of Washington, D.C. Dr. Nevrivy, who holds a Ph.D. in molecular and cellular biology, was formerly with the D.C. firm of Sterne, Kessler, Goldstein & Fox for seven years. Dr. Nevrivy is building a team of lawyer-scientists to serve businesses, universities and inventors who seek innovative ways to lower their costs for protection of their IP without sacrificing quality.

"It's a little tricky for existing law firms to lower their fees and maintain quality because the cost structure is so built in to their way of doing things. However, a new law firm that is small and highly focused can create a cost structure de novo that works. A reduced overhead and a streamlined firm structure also mean that attorneys can provide the highest quality of work more efficiently than larger firms. It's a win-win situation, for the client and the lawyer," according to Dr. Nevrivy.

About Nevrivy Patent Law Group P.L.L.C.:

Nevrivy Patent Law Group P.L.L.C. ( is alaw firmfocusedon biotechnology and pharmaceutical patent lawthat strives to provide high quality, value-oriented legal services for clients. The firm's services include the preparation, filing and prosecution of patent applications in the U.S. and foreign countries. The firm also conducts due diligence, patentability, invalidity and non-infringement investigations and opinions in a wide variety of subject areas in biotechnology and the pharmaceutical sciences. The firm's services also include client counseling regarding intellectual property matters, including patents, trademarks and trade secrets. The firm also advises clients regarding the transfer and enforcement of intellectual property rights.


Read the full story at

Source: PRWeb
Copyright©2008 Vocus, Inc.
All rights reserved  

Related medicine news :

1. SCOLR Pharma, Inc. Announces Resignation of CEO Daniel O. Wilds
2. Daniel E. Crookshank Joins Mylan as Vice President - Investor Relations
3. Dr. Daniel Von Hoff Discusses "The Complete Phase Ib," A Clinical Trial Design Offering Faster Drug Development, Economies of Scale and Improved Therapeutic Benefit
4. MaxLife Fund Corp. Appoints Mr. Dan Schmitt, Mr. Randy Delkus and Mr. Daniel E. Kahan to its Board of Directors
5. Daniel Corcoran named President of Anthem Blue Cross and Blue Shield in Maine
6. HealthSouth Finalizes Sale of Corporate Campus to Daniel Corporation
7. Hiemstra Appoints Daniel C. Rosenman as Vice President of Research & Development
8. Daniel Magilavy, M.D. Joins Rigel as Vice President of Clinical Research
9. Statement by Daniel W. Jones, M.D., American Heart Association President on President Bushs FY 2009 Budget Proposal
10. Vincent Corso and Daniel Trush Win 2007 Avis We Try Harder Awards
11. MaxLife Fund Corp. appoints Daniel E. Kahan, to its Advisory Board
Post Your Comments:
Related Image:
 Daniel J. Nevrivy, Ph.D., Biotech and Pharmaceutical Patent Attorney, Launches New Law Firm Aimed at Helping Clients Preserve Their Capital 
(Date:10/13/2017)... ... October 13, 2017 , ... Many families have long-term insurance that covers ... companies have a waiver for care if the client has a cognitive impairment diagnosis. ... pays for care, is often waived, so the benefits from their insurance start immediately,” ...
(Date:10/13/2017)... Abilene, Texas (PRWEB) , ... October 13, 2017 , ... ... publication this week that explains one of the most popular and least understood books ... seems like cryptic and puzzling descriptions that have baffled scholars for centuries. Many have ...
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... “America On ... Christian identity. “America On The Brink” is the creation of published author, William ... several great-grandchildren. As a WWII veteran, he spent thirty years in the Navy. ...
(Date:10/12/2017)... ... 12, 2017 , ... The company has developed a suite ... regulatory authorities worldwide. From Children’s to Adults 50+, every formula has been developed ... , These products are also: Gluten Free, Non-GMO, Vegan, Soy Free, Non-Dairy*, ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... drug delivery system that we intend to develop to enable prevention of a ... lead to severe hearing loss, especially in pediatric patients. For cisplatin, hearing loss ...
Breaking Medicine News(10 mins):
(Date:10/4/2017)... , Oct. 4, 2017 OBP ... self-contained, illuminating medical devices, today announced regulatory approval ... Surveillance Agency (or Agência Nacional de Vigilância Sanitária ... single-use, cordless surgical retractor with integrated LED light ... access, illumination and exposure of a tissue pocket ...
(Date:10/2/2017)... INDIANAPOLIS , Oct. 2, 2017  Eli Lilly ... its financial results for the third quarter of 2017 ... a conference call on that day with the investment ... performance. The conference call will begin at ... public can access a live webcast of the conference ...
(Date:10/2/2017)... , Oct. 2, 2017 Halo Labs announces the European ... system called the HORIZON at MIBio 2017 in Cambridge, ... and visible particulate matter in biopharmaceutical samples with unprecedented speed and ... the novel technique Backgrounded Membrane Imaging. ... The HORIZON subvisible particle analysis system ...
Breaking Medicine Technology: